SCHEDULE: Glazer Capital Discloses 5.53% Stake in Astria Therapeutics

Glazer Capital, LLC and Paul J. Glazer have reported a beneficial ownership of 5.53% in Astria Therapeutics, Inc. common stock.

Summary

• Glazer Capital, LLC and Paul J. Glazer collectively reported beneficial ownership of 3,155,200 shares of Astria Therapeutics, Inc. common stock.
• This ownership represents 5.53% of the total outstanding shares of Astria Therapeutics, Inc.
• The shares are held by certain funds and managed accounts for which Glazer Capital, LLC serves as investment manager.
• Paul J. Glazer, as the Managing Member of Glazer Capital, LLC, is also deemed a beneficial owner of these shares.
• Both reporting persons hold shared voting and shared dispositive power over all 3,155,200 shares.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or outlook. It is a neutral regulatory requirement.

Future Outlook

NA

Industry Context

This filing indicates an institutional investor, Glazer Capital, LLC, has taken a significant passive stake in Astria Therapeutics, Inc., a biotechnology company. Such disclosures are common and provide transparency regarding major shareholder positions, which can sometimes signal investor confidence or strategic interest in the sector, particularly in companies with ongoing clinical development or market potential.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can be viewed as a vote of confidence or a potential precursor to future engagement, though the filing states no intent to influence control.
• Company Management: Awareness of a new significant shareholder, which may lead to future communications or engagement, particularly given the certification regarding potential nominations under Rule 14a-11.

Key Dates

Keywords

Astria Therapeutics, Glazer Capital, Paul J. Glazer, Beneficial Ownership, Schedule 13G, Common Stock, Investment Adviser, Equity Stake